A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP

Br J Haematol. 2023 Aug;202(4):897-899. doi: 10.1111/bjh.18908. Epub 2023 Jun 20.

Authors

Michael D Tarantino¹, James B Bussel², Eun-Ju Lee³, Brian D Jamieson⁴

Affiliations

¹ Professor of Pediatrics and Medicine, CEO/CMO Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, Illinois, USA.
² Professor Emeritus of Pediatrics, Weill Cornell Medicine, New York, New York, USA.
³ Assistant Professor of Medicine, Weill Cornell Medical College, New York, New York, USA.
⁴ Global Drug Development, Sobi, Inc., Durham, North Carolina, USA.

PMID: 37339869
DOI: 10.1111/bjh.18908

No abstract available

Publication types

Randomized Controlled Trial
Clinical Trial, Phase III
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Benzoates / adverse effects
Humans
Hydrazines / adverse effects
Platelet Count
Purpura, Thrombocytopenic, Idiopathic* / drug therapy

Substances

eltrombopag
avatrombopag
Benzoates
Hydrazines